ONWD Share Price Performance
€4.32
-2.04 (-32.08%)
60.2% undervalued intrinsic discount
€10.87
Fair Value
Price €4.32
AnalystConsensusTarget €10.87
AnalystLowTarget €8.40
Fair Value€10.87
Share Pricen/a
Onward Medical N.V. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
ONWD Community Narratives
AN
Fair Value €10.87 60.2% undervalued intrinsic discount
Clinic And Home Neuromodulation Adoption Will Drive Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value €8.4 48.6% undervalued intrinsic discount
Challenged Reimbursement And Cash Burn Will Test Neurostimulation Thesis Yet Long Term Potential Remains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Challenged Reimbursement And Cash Burn Will Test Neurostimulation Thesis Yet Long Term Potential Remains
Catalysts About Onward Medical Onward Medical develops and commercializes neurostimulation systems intended to improve function and quality of life for people with spinal cord injury. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€8.4
48.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
155.31% p.a.
Profit Margin
5.39%
Future PE
184.7x
Price in 2029
€10.08
Clinic And Home Neuromodulation Adoption Will Drive Long Term Opportunity
Catalysts About Onward Medical Onward Medical develops neuromodulation therapies designed to restore function and improve quality of life for people with spinal cord injury and related conditions. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
€10.87
60.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
201.54% p.a.
Profit Margin
5.39%
Future PE
145.15x
Price in 2028
€13.04
Trending Discussion
Recently Updated Narratives
AN
Challenged Reimbursement And Cash Burn Will Test Neurostimulation Thesis Yet Long Term Potential Remains
Fair Value: €8.4 48.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinic And Home Neuromodulation Adoption Will Drive Long Term Opportunity
Fair Value: €10.87 60.2% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Onward Medical N.V. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.86
- -388.07%
- -1,423.09%
- 51.4%
About ONWD
- Founded
- 2014
- Employees
- 103
- CEO
- WebsiteView website
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people with SCI; ARCBCI, an implanted brain-computer interface to restore thought-driven movement. It operates in France, Germany, the Netherlands, the United Kingdom, and Switzerland. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.
